The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Stand Up To Cancer returns on August 15. The biennial fundraising event is scheduled to occur in Nashville this year, which ...

Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than half of those treated for chronic migraine who responded during the first ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...